|
**Overview**: Myasthenia Gravis Panel**Introduction**: The Myasthenia Gravis Panel is a diagnostic tool designed to screen for myasthenia gravis using serum samples. In India, myasthenia gravis (MG) affects ~20-30 per 100,000, with acetylcholine receptor antibodies (AChR Ab) positive in ~80-90 percent of generalized MG and MuSK/LRP4 in seronegative cases. High morbidity from under-testing in rural/low-SES patients with ptosis, diplopia, dysphagia, or fatigable weakness, limited autoantibody labs, delayed pyridostigmine/immunosuppression leading to myasthenic crisis or respiratory failure. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs immunoassay for AChR Ab, anti-MuSK Ab, anti-LRP4 Ab, and striational Ab over 1-2 days with high specificity, valuable for confirming autoimmune neuromuscular junction disorder. This diagnostic falls under autoimmune screening and targets patients with fluctuating weakness or thymoma association, addressing accurate detection to guide acetylcholinesterase inhibitors, steroids, or thymectomy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise antibody profiling and reducing crisis risk. Its serum-based approach ensures reliable autoantibody detection.**Other Names**: Myasthenia Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: AChR/MuSK testing standard; in India, used in neuromuscular clinics.**Purpose**: The test assesses 4 parameters including AChR Ab to guide MG screening, detect autoantibodies, inform immunosuppression.**Test Parameters**: 1. Acetylcholine Receptor Ab, 2. Anti-MuSK Ab, 3. Anti-LRP4 Ab, 4. Striational Ab.**Pretest Condition**: No fasting required; patients should report fatigable weakness.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on ptosis, dysphagia, thymoma history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated MG including crisis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or thymectomy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive AChR/MuSK indicates MG subtype, necessitating specialist input.**Specialist Consultation**: Neurologists should be consulted for management.**Additional Supporting Tests**: Repetitive nerve stimulation, single-fiber EMG for confirmation.**Test Limitations**: Seronegative MG possible; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuromuscular Studies India 2023. |
